Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Vincristine liposomal (Marqibo) for relapsed or refractory acute lymphoblastic leukaemia – third line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Acute lymphoblastic leukaemia is a cancer of the blood. It causes the bone marrow to make large numbers of abnormal white blood cells, which means the bone marrow is less able to make normal red blood cells, white blood cells, and platelets. Treatments for acute lymphoblastic leukaemia are often successful at first, especially in children, but the disease often returns and is much more difficult to treat in adults.
Vincristine liposomal is a new form of a chemotherapy drug called vincristine that may be more effective and less toxic than current chemotherapy because it is encapsulated in a protective shell. It is delivered straight into the bloodstream via a drip. Some studies have suggested vincristine liposomal may be helpful for people whose first two treatments have already failed and the leukaemia has returned. It is now being studied to see how well it works and whether it is safe for patients to use.
If vincristine liposomal is licenced for use in the UK, it could be a new treatment option for patients with acute lymphoblastic leukaemia that may improve survival when two current treatments have already stopped working. It may also cause fewer side effects than the current form of vincristine. Indexing Status Subject indexing assigned by CRD MeSH Humans; Liposomes; Neoplasm Recurrence, Local; Phospholipids; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vincristine Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000411 Date abstract record published 04/03/2016 |